1st quarter 2009: Net result € 14.3 million
Back to list28 apr
Financial highlights
− Sales rose 0.5% (5.9% at constant exchange rates). The substantial increase at Direct & Institutional was partly offset by the substantial price and margin decline on generic pharmaceuticals due to the preference policy (Pharmacies NL), and the depreciation of the Polish zloty (Pharmacies International).
− Operating result declined by € 9,0 million (28%), of which € 7.4 million at Pharmacies NL.
− 2009 outlook: sales + 5% at constant exchange rates.
Financial highlights
− Sales rose 0.5% (5.9% at constant exchange rates). The substantial increase at Direct & Institutional was partly offset by the substantial price and margin decline on generic pharmaceuticals due to the preference policy (Pharmacies NL), and the depreciation of the Polish zloty (Pharmacies International).
− Operating result declined by € 9,0 million (28%), of which € 7.4 million at Pharmacies NL.
− 2009 outlook: sales + 5% at constant exchange rates.
Operational highlights
− Pharmacies Netherlands: progress achieved in adapting business operations to changed market conditions.
o Mediq Pharmacy marketing campaign successful.
o Implementation of reorganisation on track.
o First agreement on additional services concluded with healthcare insurer.
− Pharmacies International: restructuring on track.
− Direct & Institutional:
o Direct activities developing as planned.
o Institutional market influenced by financial situation Dutch hospitals and institutions and devaluation Norwegian crown.
Contact
Mediq
Hertogswetering 159
3543 AS Utrecht
the Netherlands
T +31 30 282 19 11
F +31 30 289 66 50
Investors
Catrien van Buttingha Wichers
Corporate Communication Director
T +31 30 2821609
M +31 6 5339 3665
catrien.van.buttingha@mediq.com
Press
Ynte Hoekstra, Manager Corporate Communications
T +31 (0)30 282 1061
M +31 (0)6 2219 7204
ynte.hoekstra@mediq.com
Annegees van Linge (on maternity leave)
annegees.van.linge@mediq.com